Comparison of the efficacy and safety of biological agents in patients with systemic juvenile idiopathic arthritis: A Bayesian network meta-analysis of randomized controlled trials.

CONCLUSION: In patients with sJIA, canakinumab had the highest probability of being the best treatment in terms of the modified ACRpedi30 response rate; neither of the tested biological agents were associated with a significant risk of serious adverse events. PMID: 33191906 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research